HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Statins, ezetimibe and PCSK9 inhibitors reverse plaque once LDL falls below about 90 mg/dL

Louis Nervegna · Mar 22, 2026 · ♥ 2 reactions · 0 comments · original Facebook post
Plaque, CAC & CT angiographyStatinsPCSK9, ezetimibe & newer drugs
↻ This is a repost. The main version (highest ranked) is Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs · Aug 12, 2025.
AI summary & key facts

Louis shares a chart of all major randomized trials showing plaque regression versus LDL achieved. Reversal of total atheroma volume appears once LDL drops below roughly 90 mg/dL; the best medication result was a 17% TAV reduction with statins in Japan-ACS.

(no text — see the shared post below)

Research cited

Statins, ezetimibe, and PCSK9 inhibitors reverse soft plaque and reduce total plaque.

A summary of all the major randomized controlled trials showing plaque reversal, using:

The x-axis is LDL cholesterol in units of mmol/L. (Multiply by 40 to convert to mg/dL.)

The y-axis is decrease in Total Atheroma Volume (TAV) in percent. This is a measure of total plaque volume.

Reference:

Paper · Journal of the American College of Cardiology · 2022Coronary Atherosclerotic Plaque Regressionjacc.org

The chart shows that it is possible to start seeing reversal of total plaque volume (TAV) with medication once the LDL-C starts getting below roughly 90mg/dL.

The best result achieved with medication was using statins in the Japan-ACS trial. This lead to a massive 17% reduction in total atheroma volume (TAV) in patients with acute coronary syndrome. The dose used was 20mg atorvastatin or 4mg pitavastatin.

↪ Japan-ACS: pitavastatin and atorvastatin both regressed coronary plaque by about 17-18%

Paper · Journal of the American College of Cardiology · 2009Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndromejacc.org

The 6 trials with statins on this chart showing plaque reversal are one of the major reasons why they remain standard of care in high risk patients.

Total atheroma volume (TAV) refers to the overall volume of plaque buildup within the coronary arteries or within a particular set of lesions that are being studied. It is a measure of the total plaque burden, and is assessed in these studies using accurate imaging techniques like intravascular ultrasound (IVUS) or coronary computed tomography angiography (CCTA). TAV includes all types of plaque, both calcified and soft plaque.

The graph shows the change in the total atheroma (plaque) volume compared to baseline. For example, a 6.5% reduction in TAV would mean that the total plaque volume in the area being measured by IVUS or CT-angiogram is now 6.5% smaller than it was at baseline.

You can see past posts in the group on the topic of reversing plaque by searching for the tag #reverseHD.

#reverseHD #statinrctsHD #statinsHD #ezetimibeHD #pcsk9HD #tavHD #pavHD #ivusHD #ctaHD #statinreverseHD #japanacsHD #pcsk9reverseHD #ezetimibereverseHD

No photo description available.
← newer: Chelation therapy for heart disease: TACT showed some signalolder: YELLOW-III: statin plus evolocumab thickened fibrous caps ov →